HCPCS · Chemotherapy treatment J9271 Injection, pembrolizumab, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 56.12M services · est. ▲ 8.0% YoY · 40,976 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 28.22M observed fee-for-service services

See the national market for J9271 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 16.14M services · est. ▲ 39.7% YoY · 14,450 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 8.29M observed fee-for-service services

See the national market for J9144 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9299 Injection, nivolumab, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 15.17M services · est. ▼ 10.5% YoY · 7,012 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 7.88M observed fee-for-service services

See the national market for J9299 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9267 Injection, paclitaxel, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 13.90M services · est. ▼ 5.8% YoY · 15,885 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 7.03M observed fee-for-service services

See the national market for J9267 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9263 Injection, oxaliplatin, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 13.79M services · est. ▲ 1.9% YoY · 7,954 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 7.04M observed fee-for-service services

See the national market for J9263 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9025 Injection, azacitidine, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 5.34M services · est. ▲ 0.2% YoY · 2,749 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2.70M observed fee-for-service services

See the national market for J9025 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9030 Bcg live intravesical instillation, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 3.80M services · est. ▼ 3.2% YoY · 15,884 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.93M observed fee-for-service services

See the national market for J9030 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9312 Injection, rituximab, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 2.53M services · est. ▲ 9.7% YoY · 5,981 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.28M observed fee-for-service services

See the national market for J9312 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9264 Injection, paclitaxel protein-bound particles, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.63M services · est. ▼ 22.5% YoY · 1,198 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 840,201 observed fee-for-service services

See the national market for J9264 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9041 Injection, bortezomib, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.21M services · est. ▼ 17.9% YoY · 5,084 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 629,937 observed fee-for-service services

See the national market for J9041 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9190 Injection, fluorouracil, 500 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.20M services · est. ▲ 2.7% YoY · 27,545 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 600,546 observed fee-for-service services

See the national market for J9190 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9171 Injection, docetaxel, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.06M services · est. ▼ 26.6% YoY · 2,627 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 536,334 observed fee-for-service services

See the national market for J9171 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 1.05M services · est. ▲ 488.6% YoY · 2,766 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 512,172 observed fee-for-service services

See the national market for Q5123 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9045 Injection, carboplatin, 50 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 853,491 services · est. ▲ 2.9% YoY · 26,188 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 429,420 observed fee-for-service services

See the national market for J9045 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9035 Injection, bevacizumab, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 761,121 services · est. ▼ 22.0% YoY · 97,318 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 381,211 observed fee-for-service services

See the national market for J9035 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 733,454 services · est. · 1,331 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 362,529 observed fee-for-service services

See the national market for Q5129 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9119 Injection, cemiplimab-rwlc, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 666,380 services · est. ▲ 174.1% YoY · 208 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 336,019 observed fee-for-service services

See the national market for J9119 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 574,986 services · est. ▲ 212.1% YoY · 1,221 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 307,370 observed fee-for-service services

See the national market for Q5126 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9173 Injection, durvalumab, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 530,025 services · est. ▲ 11.9% YoY · 793 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 264,479 observed fee-for-service services

See the national market for J9173 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9177 Injection, enfortumab vedotin-ejfv, 0.25 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 500,075 services · est. · 261 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 266,304 observed fee-for-service services

See the national market for J9177 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9395 Injection, fulvestrant, 25 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 465,046 services · est. ▼ 1.3% YoY · 3,257 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 232,898 observed fee-for-service services

See the national market for J9395 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment Q5107 Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 340,390 services · est. ▼ 33.7% YoY · 883 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 169,844 observed fee-for-service services

See the national market for Q5107 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9047 Injection, carfilzomib, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2014 — first year this code appears in Part B claims

National scale 320,968 services · est. ▼ 12.5% YoY · 426 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 162,044 observed fee-for-service services

See the national market for J9047 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 318,506 services · est. ▼ 24.3% YoY · 8,307 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 160,292 observed fee-for-service services

See the national market for J9201 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment Q5118 Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 276,733 services · est. ▼ 66.2% YoY · 818 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 134,834 observed fee-for-service services

See the national market for Q5118 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9380 Injection, teclistamab-cqyv, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 219,023 services · est. · 165 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 109,242 observed fee-for-service services

See the national market for J9380 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9358 Injection, fam-trastuzumab deruxtecan-nxki, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 216,333 services · est. ▲ 79.2% YoY · 94 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 107,900 observed fee-for-service services

See the national market for J9358 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9145 Injection, daratumumab, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2017 — first year this code appears in Part B claims

National scale 216,066 services · est. ▼ 33.9% YoY · 66 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 106,512 observed fee-for-service services

See the national market for J9145 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9073 Injection, cyclophosphamide (ingenus), 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 174,107 services · est. · 229 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 92,443 observed fee-for-service services

See the national market for J9073 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9206 Injection, irinotecan, 20 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 172,272 services · est. ▼ 2.6% YoY · 2,507 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 88,367 observed fee-for-service services

See the national market for J9206 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9305 Injection, pemetrexed, not otherwise specified, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 171,944 services · est. ▼ 14.8% YoY · 551 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 88,565 observed fee-for-service services

See the national market for J9305 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9306 Injection, pertuzumab, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 166,694 services · est. ▲ 688.8% YoY · 36 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 83,142 observed fee-for-service services

See the national market for J9306 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9022 Injection, atezolizumab, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2018 — first year this code appears in Part B claims

National scale 157,558 services · est. ▼ 54.7% YoY · 229 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 92,688 observed fee-for-service services

See the national market for J9022 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J0894 Injection, decitabine, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 136,559 services · est. ▼ 17.1% YoY · 370 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 75,012 observed fee-for-service services

See the national market for J0894 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9075 Injection, cyclophosphamide, not otherwise specified, 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 127,264 services · est. · 152 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 69,825 observed fee-for-service services

See the national market for J9075 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9228 Injection, ipilimumab, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 121,168 services · est. ▲ 3.9% YoY · 125 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 64,806 observed fee-for-service services

See the national market for J9228 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9298 Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 111,214 services · est. ▲ 23.9% YoY · 97 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 62,442 observed fee-for-service services

See the national market for J9298 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9304 Injection, pemetrexed (pemfexy), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 101,980 services · est. ▲ 352.2% YoY · 216 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 54,412 observed fee-for-service services

See the national market for J9304 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9311 Injection, rituximab 10 mg and hyaluronidase CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 85,049 services · est. ▲ 23.1% YoY · 85 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 42,420 observed fee-for-service services

See the national market for J9311 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9301 Injection, obinutuzumab, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2017 — first year this code appears in Part B claims

National scale 79,115 services · est. ▲ 1304.8% YoY · 85 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 39,460 observed fee-for-service services

See the national market for J9301 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment Q5114 Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 76,419 services · est. ▲ 258.4% YoY · 239 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 45,152 observed fee-for-service services

See the national market for Q5114 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9070 Cyclophosphamide, 100 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 75,739 services · est. ▼ 29.2% YoY · 1,805 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 41,398 observed fee-for-service services

See the national market for J9070 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9181 Injection, etoposide, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 69,465 services · est. ▼ 14.3% YoY · 962 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 38,470 observed fee-for-service services

See the national market for J9181 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9071 Injection, cyclophosphamide (auromedics), 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 63,999 services · est. · 57 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 31,422 observed fee-for-service services

See the national market for J9071 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9037 Injection, belantamab mafodotin-blmf, 0.5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 63,493 services · est. · 25 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 34,400 observed fee-for-service services

See the national market for J9037 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9196 Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 61,874 services · est. ▲ 442.4% YoY · 1,123 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 32,195 observed fee-for-service services

See the national market for J9196 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9044 Injection, bortezomib, not otherwise specified, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 50,541 services · est. · 263 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 29,636 observed fee-for-service services

See the national market for J9044 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9060 Injection, cisplatin, powder or solution, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 50,229 services · est. ▼ 33.8% YoY · 1,747 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 26,363 observed fee-for-service services

See the national market for J9060 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9355 Injection, trastuzumab, excludes biosimilar, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 50,158 services · est. ▲ 157.9% YoY · 164 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 25,017 observed fee-for-service services

See the national market for J9355 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9260 Injection, methotrexate sodium, 50 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 48,311 services · est. ▲ 162.4% YoY · 2,737 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 25,242 observed fee-for-service services

See the national market for J9260 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9034 Injection, bendamustine hcl (bendeka), 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2017 — first year this code appears in Part B claims

National scale 46,098 services · est. ▲ 13.4% YoY · 105 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 25,141 observed fee-for-service services

See the national market for J9034 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9033 Injection, bendamustine hcl (treanda), 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 45,521 services · est. · 24 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 23,522 observed fee-for-service services

See the national market for J9033 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9259 Injection, paclitaxel protein-bound particles (american regent), not therapeutically equivalent to j9264, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 33,494 services · est. · 11 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 16,706 observed fee-for-service services

See the national market for J9259 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment Q5116 Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 25,096 services · est. · 59 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 12,517 observed fee-for-service services

See the national market for Q5116 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9043 Injection, cabazitaxel, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 23,179 services · est. ▲ 117.0% YoY · 75 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 11,561 observed fee-for-service services

See the national market for J9043 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9250 Methotrexate sodium, 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 22,069 services · est. ▼ 79.0% YoY · 675 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 11,311 observed fee-for-service services

See the national market for J9250 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9036 Injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 20,801 services · est. · 12 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 10,375 observed fee-for-service services

See the national market for J9036 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment Q5112 Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 16,579 services · est. · 98 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 9,122 observed fee-for-service services

See the national market for Q5112 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9280 Injection, mitomycin, 5 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 14,308 services · est. ▲ 31.5% YoY · 860 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 7,417 observed fee-for-service services

See the national market for J9280 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9394 Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 13,767 services · est. ▼ 67.4% YoY · 139 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 7,660 observed fee-for-service services

See the national market for J9394 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9325 Injection, talimogene laherparepvec, per 1 million plaque forming units CMS descriptor · HCPCS
Medicare Part B claims

First observed 2018 — first year this code appears in Part B claims

National scale 13,505 services · est. · 11 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 7,317 observed fee-for-service services

See the national market for J9325 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9354 Injection, ado-trastuzumab emtansine, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 12,110 services · est. · 12 FFS beneficiary-episodes (CY2020, all-Medicare estimate) — 7,280 observed fee-for-service services

See the national market for J9354 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9000 Injection, doxorubicin hydrochloride, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 11,654 services · est. ▼ 32.3% YoY · 380 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 5,868 observed fee-for-service services

See the national market for J9000 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9049 Injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 11,461 services · est. · 23 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 6,540 observed fee-for-service services

See the national market for J9049 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J1323 Injection, elranatamab-bcmm, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 11,204 services · est. · 31 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 5,588 observed fee-for-service services

See the national market for J1323 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9214 Injection, interferon, alfa-2b, recombinant, 1 million units CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 8,859 services · est. ▼ 73.4% YoY · 43 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 4,800 observed fee-for-service services

See the national market for J9214 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9393 Injection, fulvestrant (teva) not therapeutically equivalent to j9395, 25 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 6,270 services · est. · 56 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 3,240 observed fee-for-service services

See the national market for J9393 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9227 Injection, isatuximab-irfc, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 6,087 services · est. ▼ 85.5% YoY · 27 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3,036 observed fee-for-service services

See the national market for J9227 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9351 Injection, topotecan, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 3,992 services · est. · 25 FFS beneficiary-episodes (CY2020, all-Medicare estimate) — 2,400 observed fee-for-service services

See the national market for J9351 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9999 Not otherwise classified, antineoplastic drugs CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 3,797 services · est. ▲ 16.7% YoY · 824 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,894 observed fee-for-service services

See the national market for J9999 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9352 Injection, trabectedin, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2017 — first year this code appears in Part B claims

National scale 3,284 services · est. ▲ 21.1% YoY · 16 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,638 observed fee-for-service services

See the national market for J9352 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9281 Mitomycin pyelocalyceal instillation, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 2,807 services · est. ▼ 76.9% YoY · 11 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,400 observed fee-for-service services

See the national market for J9281 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9272 Injection, dostarlimab-gxly, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 2,707 services · est. · 11 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,350 observed fee-for-service services

See the national market for J9272 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment Q5117 Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 2,209 services · est. · 11 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,102 observed fee-for-service services

See the national market for Q5117 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment Q2050 Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1,699 services · est. · 36 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 888 observed fee-for-service services

See the national market for Q2050 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J0202 Injection, alemtuzumab, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 797 services · est. ▼ 16.0% YoY · 12 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 432 observed fee-for-service services

See the national market for J0202 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9390 Injection, vinorelbine tartrate, 10 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 749 services · est. ▲ 435.8% YoY · 27 FFS beneficiary-episodes (CY2021, all-Medicare estimate) — 426 observed fee-for-service services

See the national market for J9390 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9198 Injection, gemcitabine hydrochloride, (infugem), 100 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 521 services · est. ▲ 22.4% YoY · 32 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 260 observed fee-for-service services

See the national market for J9198 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9040 Injection, bleomycin sulfate, 15 units CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 435 services · est. ▲ 10.7% YoY · 121 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 217 observed fee-for-service services

See the national market for J9040 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment Q2043 Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 150 services · est. · 29 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 75 observed fee-for-service services

See the national market for Q2043 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9370 Vincristine sulfate, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 144 services · est. · 22 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 72 observed fee-for-service services

See the national market for J9370 → ranked groups · states · 12-yr trend

HCPCS · Chemotherapy treatment J9185 Injection, fludarabine phosphate, 50 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 90 services · est. ▲ 111.9% YoY · 12 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 45 observed fee-for-service services

See the national market for J9185 → ranked groups · states · 12-yr trend

Chemotherapeutic Agent codes